Nano Medicine Research Center

Moga, India

Nano Medicine Research Center

Moga, India
SEARCH FILTERS
Time filter
Source Type

Laxmi M.,Nano Medicine Research Center | Bhardwaj A.,Nano Medicine Research Center | Mehta S.,Nano Medicine Research Center | Mehta A.,Nano Medicine Research Center
Artificial Cells, Nanomedicine and Biotechnology | Year: 2015

The present study aimed to develop a kinetically stable nanoemulsion of artemether with improved solubility, stability and oral bioavailability. Nanoemulsion was prepared by ultrasonication technique using internal oil phase (consisted of the drug dissolved in coconut oil and span 80) and external phase (comprising tween 80 and ethanol dissolved in water). The formulations were optimized using various parameters like percentage transmittance, refractive index, drug content, viscosity, zeta potential and release rate. Stability studies were conducted for a period of 90 days using stability chambers. In vivo studies of the developed formulations were conducted on Wistar rats and data were analyzed statistically. The nanoemulsion as observed under transmission electron microscope were found to be spherical in shape with an average size of 79.0 nm and a zeta potential of -15 mV which indicated of good electrokinetic stability of nanoemulsion . Nanoemulsion was found to be clear and transparent in appearance with a percentage transmittance of 98.2. Refractive index of 1.32 of the nanoemulsion indicated the isotropic nature of the drug. Release rate of the drug from the nanoemulsion formulation was found to be quite significant (P > 0.001) as compared to the plain drug. In vivo oral bioavailability of the nanoemulsion formulation was found to be 2.6-fold higher than the plain drug (∼40%) as observed from pharmacokinetic studies. Thus it was observed that nanoemulsion proved itself as a promising alternate for improving the bioavailability of artemether. Copyright © 2013 Informa Healthcare USA, Inc.


Vohra T.,Nano Medicine Research Center | Kaur I.,Nano Medicine Research Center | Heer H.,Nano Medicine Research Center | Murthy R.R.,Nano Medicine Research Center
Cancer Nanotechnology | Year: 2013

Intratumoral and intralesional administration of anticancer drugs in gels and implantable formulations is gaining much importance on account of its advantage of site-specific delivery with highly dependable freedom from unwanted side effects. Nanolipid carriers (NLC) are the preferred vehicle due to their improved properties particularly drug loading. In the present investigation, glyceryl monostearate-oleic acid NLCs loaded with docetaxel were prepared by emulsification and ultrasonication technique and were incorporated in thermoreversible pluronic F127 gel (TRPgel) for intralesion injection to breast tissue. The NLCs were spherical particles of 113 nm size with a negative zeta potential of -32.8 and 85 % drug entrapment. In vitro drug release profile of the NLC showed 96 % drug release in 48 h following Higuchi release kinetics. NLC incorporated TRPgel showed mucoadhesive force of 3.07 dynes/cm2 and gelling temperature in the range of 32 to 37 °C. The drug entrapped gel was also subjected to in vitro cytotoxicity study in human B-16 and HeLa cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and in vivo drug distribution study in breast tissue in healthy Wistar rats. The MTT assay revealed that docetaxel-loaded NLC incorporated into gel showed lower cytotoxicity than docetaxel. However, in vivo breast tissue distribution studies showed high tissue drug concentration, sustained over a period of 60 h in comparison to docetaxel and docetaxel-loaded NLCs. These results suggest that nanolipid carrier of docetaxel in TRPgel could be a promising carrier system to deliver drug to tumor by intralesional administration for improving therapeutic benefits of docetaxel. © 2013 Springer-Verlag Wien.


PubMed | Nano Medicine Research Center
Type: Journal Article | Journal: Cancer nanotechnology | Year: 2015

Intratumoral and intralesional administration of anticancer drugs in gels and implantable formulations is gaining much importance on account of its advantage of site-specific delivery with highly dependable freedom from unwanted side effects. Nanolipid carriers (NLC) are the preferred vehicle due to their improved properties particularly drug loading. In the present investigation, glyceryl monostearate-oleic acid NLCs loaded with docetaxel were prepared by emulsification and ultrasonication technique and were incorporated in thermoreversible pluronic F127 gel (TRPgel) for intralesion injection to breast tissue. The NLCs were spherical particles of 113nm size with a negative zeta potential of -32.8 and 85% drug entrapment. In vitro drug release profile of the NLC showed 96% drug release in 48h following Higuchi release kinetics. NLC incorporated TRPgel showed mucoadhesive force of 3.07dynes/cm


PubMed | Nano Medicine Research Center
Type: Journal Article | Journal: Journal of advanced pharmaceutical technology & research | Year: 2012

Management of postoperative pain relieve suffering and leads to earlier mobilization, shortened hospital stay, reduced hospital costs, and increased patient satisfaction. An effective postoperative management is not a standardized regime rather is tailored to the needs of the individual patient, taking into account medical, psychological, and physical condition; age; level of fear or anxiety; surgical procedure; personal preference; and response to therapeutic agents given. The major goal in the management of postoperative pain is to minimize the dose of medications to lessen side effects & provide adequate analgesia. Postoperative pain is still under managed due to obstacles in implementation of Acute Pain Services due to insufficient education, fear of complications associated with available analgesic drugs, poor pain assessment and inadequate staff. This review reflects the clinical aspects of postoperative pain & its assessment & management with an emphasis on research for new analgesic molecules & delivery system.


PubMed | Nano Medicine Research Center
Type: Journal Article | Journal: Expert opinion on drug delivery | Year: 2012

Research has revealed a relationship between mitochondrial dysfunction and diseases such as diabetes, ischemia-reperfusion injury, cancer and many more. As a result, mitochondria have gained attention as a target organelle for the treatment of many diseases. Successful delivery of the drug molecule to the mitochondria could be achieved by keeping in mind the normal intracellular trafficking fate of molecules in cell as well as through the mitochondria and exploring the new possibilities to reach the target in an efficient manner.This review covers important areas such as structure and physiology of mitochondria, mitochondrial genome and its role in the diseases led by mitochondrial dysfunction, generation of reactive oxygen species and its disbalance in pathophysiological conditions and apoptosis. Further, the review focuses on various human mitochondrial diseases, particularly cancer, and strategies and methods of targeting drug and genetic materials to mitochondria. Novel nanotechnology-based carriers for mitochondria delivery are discussed with an attempt of providing readers with a current and future prospective of mitochondrial therapeutics.Numerous investigators have attempted to establish a mitochondrial drug delivery system; still, many hurdles yet remain to be overcome before mitochondrial medicine reaches clinical applications. We need to develop a delivery system to encapsulate drugs, proteins and genes that would be practically viable for scale-up and strategies to target and regulate drug release to the cytosol after endosomal escape, and thereafter to deliver the released drug to the mitochondria. Current innovations in the nanotechnology could be effectively utilized with mitochondrial medicine for designing optimal nanoparticle drug delivery system for mitochondrial diseases on clinical setting.


PubMed | Nano Medicine Research Center
Type: Journal Article | Journal: International journal of pharmaceutics | Year: 2012

Cancer cells reflect higher level of ROS in comparison to the normal cell, so they become more vulnerable to further oxidative stress induced by exogenous ROS-generating agents. Through this a novel therapeutic strategy has evolved, which involves the delivery of redox cycler-doxorubicin (DOX) to the mitochondria of cancer cell where it acts as a source of exogenous ROS production. The purpose of this study is to develop a liposomal preparation which exhibits a propensity to selectively target cancer cell along with the potential of delivering drug to mitochondria of cell. We have rendered liposomes mitocancerotropic (FA-MTLs) by their surface modification with dual ligands, folic acid (FA) for cancer cell targeting and triphenylphosphonium (TPP) cations for mitochondria targeting. The cytotoxicity, ROS production and cell uptake of doxorubicin loaded liposomes were evaluated in FR (+) KB cells and found to be increased considerably with FA-MTLs in comparison to folic acid appended, mitochondria targeted and non-targeted liposomes. As confirmed by confocal microscopy, the STPP appended liposomes delivered DOX to mitochondria of cancer cell and also showed higher ROS production and cytotoxicity in comparison to folic acid appended and non-targeted liposomes. Most importantly, mitocancerotropic liposomes showed superior activity over mitochondria targeted liposomes which confirm the synergistic effect imparted by the presence of dual ligands - folic acid and TPP on the enhancement of cellular and mitochondrial delivery of doxorubicin in KB cells.

Loading Nano Medicine Research Center collaborators
Loading Nano Medicine Research Center collaborators